Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA CAR-T cells + CD19 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Shanghai Fourth People's Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is a combination cell therapy product consisting of chimeric antigen receptor (CAR) T cells engineered to target both B-cell maturation antigen (BCMA) and CD19. The approach involves either co-infusion or dual-targeting of autologous or allogeneic T cells modified to express separate or tandem CARs against these two antigens. The mechanism aims to enhance anti-myeloma efficacy by addressing tumor heterogeneity and reducing the risk of antigen escape in relapsed/refractory multiple myeloma (R/R MM), including cases with extramedullary disease. Clinical studies have shown promising safety and efficacy profiles, with durable responses observed in early-phase trials[1][2][3][4].
- Brand names
- KQ-2003KQ2003KQ 2003P-BCMACD19-ALLO1P-BCMACD-19-ALLO1P-BCMACD 19-ALLO1
- Other names
- BCMA/CD19 dual-targeting CAR T-cell therapyanti-BCMA/CD19 CAR T cellsCART-BCMA + huCART19
02
Targets
TNFRSF9 (CD137 extracellular domain)BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on BCMA CAR-T cells + CD19 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA CAR-T cells + CD19 CAR-T cells.